Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 3.5% – Time to Sell?

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) were down 3.5% during trading on Thursday . The company traded as low as $31.87 and last traded at $31.4550. Approximately 128,938 shares were traded during trading, a decline of 92% from the average daily volume of 1,629,550 shares. The stock had previously closed at $32.60.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Zacks Research raised Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. Citigroup upped their price objective on Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. UBS Group reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, October 20th. JPMorgan Chase & Co. boosted their target price on Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.50.

Olema Pharmaceuticals Trading Down 4.9%

The business has a 50-day moving average of $17.14 and a 200-day moving average of $9.84. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -16.57 and a beta of 1.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). As a group, research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Institutional Trading of Olema Pharmaceuticals

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its stake in Olema Pharmaceuticals by 4.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 349,023 shares of the company’s stock valued at $1,312,000 after purchasing an additional 16,073 shares during the period. Deutsche Bank AG grew its holdings in shares of Olema Pharmaceuticals by 38.1% during the first quarter. Deutsche Bank AG now owns 54,329 shares of the company’s stock worth $204,000 after buying an additional 14,998 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Olema Pharmaceuticals by 208.9% during the first quarter. Invesco Ltd. now owns 50,810 shares of the company’s stock worth $191,000 after buying an additional 34,362 shares during the last quarter. Nuveen LLC acquired a new position in Olema Pharmaceuticals in the 1st quarter valued at about $1,295,000. Finally, Brooklyn Investment Group purchased a new stake in Olema Pharmaceuticals during the 1st quarter valued at approximately $71,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.